NASDAQ:STRO | Free Cash Flow | SUTRO BIOPHARMA, INC.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$42.26M
2025-12-31-$26.44M
2025-03-31-$67.88M
2024-12-31-$71.74M
2024-03-31-$64.74M
2023-12-31$14.07M
2023-03-31-$60.99M
2022-12-31-$23.86M
2022-03-31-$35.26M
2021-12-31-$21.58M
2021-03-31-$30.43M
2020-12-31-$18.88M
2020-03-31-$18.73M$763,000.00-$19.5M
2019-12-31-$13.16M
2019-03-31-$20.15M$276,000.00-$20.42M
2018-12-31-$5.94M$798,000.00-$6.73M
2018-03-31-$15.01M$364,000.00-$15.37M
2017-12-31-$4.84M$657,000.00-$5.5M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$177.23M
2024-12-31-$191.54M
2023-12-31-$111.62M
2022-12-31$3.55M
2021-12-31-$81.68M
2020-12-31-$67.8M
2019-12-31-$65.02M
2018-12-31$12.68M$1.56M$11.13M
2017-12-31-$37.07M$3.32M-$40.39M
2016-12-31-$13.15M$4.39M-$17.55M-1030.96%

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.